Public Health Action

International Union Against Tuberculosis and Lung Disease

Health solutions for the poor

+

VOL 8 NO 2 PUBLISHED 21 JUNE 2018

CORRESPONDENCE

Pyridoxine for patients suffering from drug-susceptible tuberculosis in India

M. Bhargava,^{1,2} A. Bhargava^{2,3}

http://dx.doi.org/10.5588/pha.18.0017

soniazid (INH) is known to cause interference with vitamin B6 metabolism, leading to the deficiency of this micronutrient and resultant peripheral neuropathy. A guidance document for nutritional care and support for patients with tuberculosis (TB), published in 2017 in India, 1 recommended a dose of 10 mg pyridoxine. This is higher than the usual recommended dietary allowance, keeping in view the INH used in the treatment regimen.1 Although the 2013 World Health Organization guidelines did not mention dosage, they recommended pyridoxine supplementation with INH-containing treatment regimens for all pregnant and lactating women, as well as for people with conditions such as human immunodeficiency virus (HIV) infection, alcohol dependence, malnutrition, diabetes mellitus (DM), chronic liver disease or renal failure, without making specific reference to drug susceptibility status.²

The current (2016) Indian technical operational guidelines recommend the addition of 50 or 100 mg pyridoxine for drug-resistant TB (DR-TB) adults weighing 16–25 kg and ≥26 kg, respectively.³ However, there is no such recommendation for drug-susceptible TB patients. The technical guidelines published in 2005 clearly mentioned that patients at risk of INH-induced peripheral neuropathy, such as those with alcohol dependence, malnutrition and DM, should be administered 10 mg pyridoxine as prevention. It also recommended routine administration of pyridoxine in communities with poor health and nutritional status, irrespective of drug susceptibility status.4 The result was that pyridoxine was prescribed routinely to all patients, irrespective of drug susceptibility status, until the 2016 guidelines came into effect in India.

The frequency of peripheral neuritis ranges from 2% to 44% in HIV-negative individuals, and is four-fold higher among those with HIV co-infection.⁵ Other comorbidities, such as undernutrition, alcohol dependence and DM, are also not infrequent among Indian patients: a third of adult men and women were found to have chronic undernutrition (body mass index [BMI] <18.5 kg/m²) according to the 2005–2006

National Family Health Survey.⁶ In a large cohort study in rural India, BMI was <16.0 kg/m² in half of adult males, and <15.0 kg/m² in adult females.⁷ A study from South India suggests that almost half of patients with TB either have DM or are pre-diabetic.⁸

To make TB treatment truly patient-centred, it is important for the nutrition component to be constantly kept in mind at policy level, at the very least to prevent drug-induced problems leading to possible loss to follow-up and resultant drug resistance. The additional cost of providing 10 mg of pyridoxine, when weighed against the benefits, is irrelevant from both the patient and the programme perspective. Pyridoxine should be prescribed to all patients, irrespective of their drug susceptibility status.

References

- 1 Revised National Tuberculosis Control Programme. Guidance document on nutritional care and support for patients with tuberculosis in India, 2017. New Delhi, India: Central TB Division, Ministry of Health and Family Welfare, Government of India, 2017.
- 2 World Health Organization. Guideline: nutritional care and support for patients with tuberculosis. Geneva, Switzerland: WHO, 2013.
- 3 Central TB Division. Technical and operational guidelines for TB control in India, 2016. Chapter 3. Case finding and diagnosis strategy. New Delhi, India: Ministry of Health and Family Welfare, Government of India, 2016.
- 4 Central Tuberculosis Division, Revised National Tuberculosis Control Programme. Technical and operational guidelines for tuberculosis control. New Delhi, India: Directorate General of Health Services, Ministry of Health and Family Welfare, Government of India, 2005.
- 5 Marks D J, Dheda K, Dawson R, Ainslie G, Miller R F. Adverse events to antituberculosis therapy: influence of HIV and antiretroviral drugs. Int J STD AIDS 2009; 20: 339–345.
- 6 Ministry of Health and Family Welfare, Government of India. National Family Health Survey (NFHS-3) 2005–06. Volume I. Mumbai, India: International Institute for Population Sciences, 2007.
- 7 Bhargava A, Chatterjee M, Jain Y, et al. Nutritional status of adult patients with pulmonary tuberculosis in rural central India and its association with mortality. PLOS ONE 2013; 8: e77979.
- 8 Viswanathan V, Kumpatla S, Aravindalochanan V, et al. Prevalence of diabetes and pre-diabetes and associated risk factors among tuberculosis patients in India. PLOS ONE 2012; 7: e41367.

AFFILIATIONS

- Department of Community Medicine, Yenepoya Medical College, Mangalore, India
- 2 Centre for Nutrition Studies, Yenepoya University, Mangalore, India
- 3 Department of Internal Medicine, Yenepoya Medical College, Mangalore, India

CORRESPONDENCE

Madhavi Bhargava Department of Community Medicine Yenepoya Medical College University Road Deralakatte, Mangalore, Karnataka 575018 India -mail: madhavi.bhargava@ yenepoya.edu.in

Conflicts of interest: none declared

KEY WORDS

isoniazid; peripheral neuropathy; nutrition

Received 19 March 2018 Accepted 20 April 2018

PHA 2018; 8(2): 97 © 2018 The Union